A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants

Diğer sürümleri göster (1)

vaccines include mRNA-containing lipid nanoparticles or adenoviral vectors that encode the SARS-CoV-2 Several vaccines have been introduced to combat the coronavirus infectious disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current SARS-CoV-...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Jiang, Linglei, Driedonks, Tom A.P., Jong, Wouter S.P., Dhakal, Santosh, van den Berg van Saparoea, H. Bart, Sitaras, Ioannis, Zhou, Ruifeng, Caputo, Christopher, Littlefield, Kirsten, Lowman, Maggie, Chen, Mengfei, Lima, Gabriela, Gololobova, Olesia, Smith, Barbara, Mahairaki, Vasiliki, Richardson, M. Riley, Mulka, Kathleen R., Lane, Andrew P., Klein, Sabra L., Pekosz, Andrew, Brayton, Cory F., Mankowski, Joseph L., Luirink, Joen, Villano, Jason S., Witwer, Kenneth W.
Materyal Türü: Online Makale Metin
Dil:English
Baskı/Yayın Bilgisi: Cold Spring Harbor Laboratory 2022
Konular:
Article
Online Erişim:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820665/
https://www.ncbi.nlm.nih.gov/pubmed/35132418
http://dx.doi.org/10.1101/2021.06.28.450181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820665/
https://www.ncbi.nlm.nih.gov/pubmed/35132418
http://dx.doi.org/10.1101/2021.06.28.450181

Benzer Materyaller